| Field | Specification |
|---|---|
| Target | |
| Alternative names | Serine palmitoyltransferase 1;2.3.1.50;Long chain base biosynthesis protein 1;LCB 1;Serine-palmitoyl-CoA transferase 1;SPT 1;SPT1;SPTLC1;LCB1; |
| UniProt # | |
| Host | |
| Clonality | |
| Isotype | |
| Reactivity | |
| Applications | |
| Immunogen | A synthetic peptide corresponding to a sequence at the C-terminus of human SPTLC1, different from the related mouse sequence by three amino acids. |
| Molecular weight | |
| Purification | |
| Reconstitution | |
| Cellular localization | |
| Concentration | |
| Form | Lyophilized |
| Storage | |
| Catalog no. (Mfr.) | |
| Main SKU |
Product Overview
This rabbit polyclonal antibody recognizes serine palmitoyltransferase 1 (gene SPTLC1) in human samples and is validated for flow cytometry, ICC/IF, IHC and Western blot. The predicted molecular weight is 52.7 kDa, and the supplier reports an observed band at about 53 kDa.
Serine palmitoyltransferase 1 (SPTLC1) is a core subunit of serine palmitoyltransferase, which carries out the first and rate-limiting step of sphingolipid synthesis by joining serine and palmitoyl-CoA. It pairs with SPTLC2 or SPTLC3 to form the catalytic core, and SPTLC1 mutations cause hereditary sensory and autonomic neuropathy type 1.
| Target | Serine palmitoyltransferase 1 (gene SPTLC1; UniProt O15269, human) |
|---|---|
| Host / Clonality / Isotype | Rabbit / Polyclonal / Rabbit IgG |
| Reactivity | Human |
| Form | Lyophilized |
| Formulation | Per vial: 0.9 mg NaCl; 0.2 mg Na2HPO4; 0.05 mg NaN3; plus stabilizers |
| Calculated MW | 52.7 kDa |
| Observed MW | 53 kDa |
| Storage | As supplied: −20 °C for up to 12 months from receipt. After reconstitution: 4 °C for up to 1 month, or aliquot and keep at −20 °C for up to 6 months. Avoid repeated freeze–thaw cycles. |
Validated Applications
| Western blot | 0.1–0.5 µg/mL (Human) |
|---|---|
| IHC (paraffin sections) | 0.5–1 µg/mL (Human) |
| Immunocytochemistry / Immunofluorescence | 2 µg/mL (Human) |
| Flow cytometry (fixed cells) | 1–3 µg/1×106 cells (Human) |
Samples with a confirmed band (WB): human Hacat cells, human A431 cells, human SIHA cells, human U251 cells.
Recommended loading (WB): 20–40 µg of total protein per lane.
Conditions in the example images (WB): 5–20% gradient SDS-PAGE under reducing conditions, 30 µg lysate per lane, transfer to nitrocellulose membrane, blocking in 5% non-fat milk, primary antibody at 0.5 µg/mL overnight at 4 °C, HRP-conjugated secondary antibody at 1:5000, ECL detection.
Samples with confirmed staining (IHC): human intestinal cancer tissue.
Recommended antigen retrieval: heat-mediated, in TE buffer (pH 9.0); citrate buffer (pH 6.0) can be used instead.
Conditions in the example images (IHC): heat-mediated antigen retrieval in citrate buffer (pH 6).
Samples with confirmed staining (ICC/IF): U2OS cells.
Samples with a confirmed signal (flow cytometry): U2OS cells.
Immunogen
Synthetic peptide from the C-terminal region of human SPTLC1. It differs from the mouse sequence at three residues.
Reactivity Notes
The supplier lists reactivity with human. UniProt places serine palmitoyltransferase 1 in the endoplasmic reticulum membrane. Tissue expression noted by UniProt (human): Widely expressed. The samples tested by the supplier (listed above) are a practical starting point for positive controls.
Safety
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
